SEC Form 4 · accession 0001209191-15-058197
PORTOLA PHARMACEUTICALS INC · PTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Lis
Officer — Chief Executive Officer · Director
Period of report
Jun 30, 2015
Accepted (ET)
Jul 1, 2015 · 6:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001269021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 30, 2015 | M | 15,000 | $7.00 | A | 15,000 | D | |
| Common StockF2,F1 | Jun 30, 2015 | S | 5,400 | $44.026 | D | 9,600 | D | |
| Common StockF3,F1 | Jun 30, 2015 | S | 9,600 | $44.73 | D | 0 | D | |
| Common StockF1 | Jul 1, 2015 | M | 15,000 | $7.00 | A | 15,000 | D | |
| Common StockF4,F1 | Jul 1, 2015 | S | 14,900 | $45.536 | D | 100 | D | |
| Common StockF5,F1 | Jul 1, 2015 | S | 100 | $46.07 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $7.00 | Jun 30, 2015 | M | 15,000 | D | Mar 8, 2012 | Mar 8, 2022 | Common Stock | 15,000 | 64,386 | D |
| Stock Option (Right to Buy) | $7.00 | Jul 1, 2015 | M | 15,000 | D | Mar 8, 2012 | Mar 8, 2022 | Common Stock | 15,000 | 49,386 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2015.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.44 to $44.43, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2), (3), (4), and (5) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.44 to $45.17, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.94 to $45.89, inclusive.
- F5These shares were sold in a single transaction at a price of $46.07.